| Today's Big NewsApr 3, 2023 |
| By Nick Paul Taylor BioNTech is putting its COVID-19 vaccine dollars to work to add a new modality to its pipeline. Sitting on $15 billion, the German biotech has doled out $170 million upfront for the rights to two antibody-drug conjugates (ADC) in development at China’s Duality Biologics. |
|
|
|
By James Waldron The FDA has thrown a curveball to Ascendis, bringing the company's hypoparathyroidism drug approval request to a screeching halt less than a month before a decision was due. |
By Max Bayer Opthamology-focused gene therapy biotech Vedere Bio II, the successor to a Novartis-bought biotech that was scooped up in 2020, is closing up shop after failing to impress in preclinical studies. |
By Annalee Armstrong Pardes Biosciences, launched in 2020 to find treatments in the height of the pandemic, will seek strategic alternatives after its antiviral for COVID-19 failed to clear the virus during a phase 2 trial. |
By Nick Paul Taylor Takeda really wants to land a hit on celiac disease. Not content with having just three pipeline prospects, the Japanese drugmaker has partnered with Innate Pharma to attack the disease with another modality: ADCs. |
By James Waldron Aridis has laid off a fifth of its workforce in the wake of AstraZeneca’s “surprise” move to terminate its pneumonia collaboration over a payment dispute. |
By Max Bayer The lab of gene editing pioneer David Liu is out with new research touting the potential of base editing to bolster existing spinal muscular atrophy treatments. The researchers said that when combined with an FDA-approved treatment, therapeutic benefits were significantly extended. |
By Ben Adams The pharmaceutical industry is making a comeback in the reputation stakes while every other industry around it is falling in Americans’ estimations as we edged toward a possible banking crisis in March. |
By Conor Hale The Prima system aims to partially restore the ability to see at the center of a person’s visual field, the area most affected by the type of age-related macular degeneration known as dry AMD. |
By Kevin Dunleavy After Johnson & Johnson’s initial victory in its attempt to resolve talc lawsuits through a bankruptcy ploy, little has gone the way of the company. On Friday, J&J took another courtroom defeat as the Third Circuit rejected its bid to delay an order dismissing the bankruptcy. |
By Robert King CMS finalized a 3.3% pay bump to Medicare Advantage plans for 2024 after proposing a 1% raise that some plans saw as a cut, and will phase in changes to risk adjustment over three years. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss how 2023 is shaping up to be much the same as last year when it comes to financing trends for biotechs. We also cover Emergent's Narcan winning the first over-the-counter approval for an opioid-overdose drug and more of this week's top headlines. |
|
|---|
|
|
Whitepaper The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
Whitepaper We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
Whitepaper How advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
Whitepaper This paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
Whitepaper For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
_updated.png)
.jpg/BioNTech_Headquarters+%281%29.jpg/167e5960a54e83877f8175af4513e28f)
.png)
